GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
ARYX THERAPEUTICS I (ARYX) [hlAlert]

Rating:
Sector Outperform
ARYX
down 99.96 %

ARYX THERAPEUTICS I (ARYX) rated Sector Outperform with price target $16 by CIBC Wrld Mkts

Posted on: Friday,  Dec 21, 2007  8:25 AM ET by CIBC Wrld Mkts

CIBC Wrld Mkts rated Sector Outperform ARYX THERAPEUTICS I (OTCBB: ARYX) on 12/21/2007, when the stock price was $8.75.
Since then, ARYX THERAPEUTICS I has lost 99.97% as of 08/27/2015's recent price of $0.00.
If you would have followed this CIBC Wrld Mkts's recommendation on ARYX, you would have lost 99.96% of your investment in 2806 days.

ARYx Therapeutics is a biopharmaceutical company focused on developing a portfolio of internally discovered product candidates designed to eliminate known safety issues associated with well-established, commercially successful drugs. ARYx uses its RetroMetabolic Drug Design(TM) technology to design structurally unique molecules that retain the efficacy of these original drugs but are metabolized through a potentially safer pathway to avoid specific adverse side effects associated with these compounds. ARYx currently has three products in Phase 2 clinical trials: ATI-7505 for the treatment of various gastrointestinal disorders, ATI-5923 for the treatment of patients at risk for the formation of dangerous blood clots, and ATI-2042 for the treatment of atrial fibrillation.

CIBC World Markets strives to deliver leading edge investment research to investing clients through our multi-faceted, firm-wide research product offering. Our research has consistently been recognized as a top research source for its breadth of coverage, industry knowledge and quality of work in generating profitable and timely investment ideas. We provide in-depth coverage for all of the major sectors of the Canadian economy and select coverage of U.S. companies. Our analytical teams remain committed to identifying trends early and developing exploitable investment opportunities across the market capitalization spectrum. With the continued growth in quantitative and computerized investing strategies, we have also developed leading edge quantitative and technical research products to partner with our fundamental approach. Our products are available through several automated avenues: email, website, and third-party market vendors. Client service is our driving force and we constantly advance in offering greater product customization options.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
12/21/2007 8:25 AM Buy
None
8.75 16.00
as of 8/27/2015
1 Week up  66.66 %
1 Month up  42.85 %
3 Months up  50.00 %
1 YTD down  -54.54 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy